Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease

20141,630 citationsJournal Articlebronze Open Access

Authors

Rachelle S. Doody · Baylor College of Medicine

Ronald G. Thomas · University of California, San Diego

Martin R. Farlow · Indiana University

Takeshi Iwatsubo · Tokyo University of Science

Bruno Vellas · Centre Hospitalier Universitaire de Toulouse

Steven Joffe · University of Pennsylvania

Karl Kieburtz

Abstract

Solanezumab, a humanized monoclonal antibody that binds amyloid, failed to improve cognition or functional ability. (Funded by Eli Lilly; EXPEDITION 1 and 2 ClinicalTrials.gov numbers, NCT00905372 and NCT00904683.).

Topics & Keywords

Alzheimer's disease research and treatments S100 Proteins and Annexins Health Systems, Economic Evaluations, Quality of Life

Publication Details

Published in: New England Journal of Medicine

Volume 370, Issue 4, pp. 311-321

DOI: 10.1056/nejmoa1312889

Field-Weighted Citation Impact: 109.41

Command Palette

Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease

Authors

Abstract

Topics & Keywords

Publication Details